131 related articles for article (PubMed ID: 37924530)
21. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
[TBL] [Abstract][Full Text] [Related]
23. The absence of multiple atypical nevi in germline CDKN2A mutations: Comment on "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome".
Ipenburg NA; Gruis NA; Bergman W; van Kester MS
J Am Acad Dermatol; 2016 Oct; 75(4):e157. PubMed ID: 27646763
[No Abstract] [Full Text] [Related]
24. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
25. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
[TBL] [Abstract][Full Text] [Related]
26. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
[TBL] [Abstract][Full Text] [Related]
27. Genetic testing for familial melanoma.
Primiero CA; Maas EJ; Wallingford CK; Soyer HP; McInerney-Leo AM
Ital J Dermatol Venerol; 2024 Feb; 159(1):34-42. PubMed ID: 38287743
[TBL] [Abstract][Full Text] [Related]
28. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
[TBL] [Abstract][Full Text] [Related]
29. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
30. Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.
Yang XR; Jessop L; Myers T; Amundadottir L; Pfeiffer RM; Wheeler W; Pike KM; Yuenger J; Burdett L; Yeager M; Chanock SJ; Tucker MA; Goldstein AM
Fam Cancer; 2011 Sep; 10(3):545-8. PubMed ID: 21614589
[TBL] [Abstract][Full Text] [Related]
31. Lack of association between CDKN2A germline mutations and survival in patients with melanoma: A retrospective cohort study.
Ipenburg NA; El Sharouni MA; van Doorn R; van Diest PJ; van Leerdam ME; van der Rhee JI; Goeman J; Kukutsch NA;
J Am Acad Dermatol; 2022 Aug; 87(2):479-482. PubMed ID: 34695526
[No Abstract] [Full Text] [Related]
32. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933
[TBL] [Abstract][Full Text] [Related]
33. Molecular genetics of familial cutaneous melanoma.
Haluska FG; Hodi FS
J Clin Oncol; 1998 Feb; 16(2):670-82. PubMed ID: 9469357
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
[TBL] [Abstract][Full Text] [Related]
35. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E
Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703
[TBL] [Abstract][Full Text] [Related]
36. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
[TBL] [Abstract][Full Text] [Related]
37. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
[TBL] [Abstract][Full Text] [Related]
38. Germline p16 mutations in familial melanoma.
Hussussian CJ; Struewing JP; Goldstein AM; Higgins PA; Ally DS; Sheahan MD; Clark WH; Tucker MA; Dracopoli NC
Nat Genet; 1994 Sep; 8(1):15-21. PubMed ID: 7987387
[TBL] [Abstract][Full Text] [Related]
39. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
40. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
Levin T; Mæhle L
Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]